In a research report issued Friday, Jefferies analyst Matthew Andrews assumed coverage on shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), with a Buy rating and a $7.00 price …
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) announced that it has submitted a New Drug Application (NDA) under section 505(b)(2) with the U.S.
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) announced an update to the agenda for its December 1, 2016 Analyst & Investor Event. Dr.
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced an upcoming presentation at the 15th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) provided a business update and reported financial results for the three and nine months ended September 30, 2016. Corporate Highlights …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that the Company and investigators will be presenting two e-posters at the European Congress on Emergency Medicine (ECEM), …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced the initiation of the Phase 3 IAP312 study of Zalviso® (sufentanil sublingual tablet system), an investigational product candidate being …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that Dr. Shankar Lakshman, a board-certified plastic surgeon and AcelRx clinical investigator, will present a subgroup analysis from …
AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX) just announced positive top-line results from its third, final Phase 3 trial of pipeline drug ARX-04 designed to treat …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will announce the results of its multicenter, open-label Phase 3 clinical study of ARX-04, known as SAP303. The study …
